Ascendis Pharma A (ASND) Receivables - Net (2012 - 2026)

Ascendis Pharma A has disclosed Receivables - Net across 15 years of filings, most recently posting $209.2 million for Q1 2026.

• Receivables - Net for Q1 2026 came in at $209.2 million, up 198.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $209.2 million (up 198.22% YoY), and the FY2025 annual result was $164.5 million, down 7.41% from the prior year.
• Receivables - Net came in at $209.2 million for Q1 2026 at Ascendis Pharma A, up from $164.5 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $209.2 million in Q1 2026 to a low of $4.7 million in Q2 2022.
• The 5-year median for Receivables - Net is $38.6 million (2023), against an average of $69.1 million.
• Across the five-year window, Receivables - Net jumped 8906.72% in 2022 and slipped 7.41% in 2025, its largest moves.
• Ascendis Pharma A's Receivables - Net stood at $12.2 million in 2022, then soared by 217.65% to $38.6 million in 2023, then surged by 360.35% to $177.7 million in 2024, then dropped by 7.41% to $164.5 million in 2025, then rose by 27.15% to $209.2 million in 2026.
• The last three Receivables - Net figures came in at $209.2 million (Q1 2026), $164.5 million (Q4 2025), and $157.5 million (Q3 2025), per Business Quant data.